Fig. 6
Ezrin promoted myoblast differentiation and fusion through the PKA-MyoG/MEF2C signaling pathway. A RNA-seq analysis of the PKA signaling pathway in C2C12 myoblasts with overexpression or knockdown of Ezrin at 6 days. n = 3. B Western blot for the indicated proteins in myoblasts treated with Ezrin overexpression or knockdown for 6 days. C–J Quantitative assays for the indicated proteins were performed 6 days after myoblast differentiation following Ezrin overexpression or knockdown. Three independent experiments were performed, n = 3, *P < 0.05 vs. Ad-Null; #P < 0.05 vs. Ad-Null. K Typical image of MyHC staining in differentiated C2C12 myoblasts treated with Ad-Ezrin with or without H-89 (10–5 mol/L) or Ad-shEzrin with or without N6-Bz-cAMP (10–5 mol/L). Red fluorescence indicates MyHC; DAPI indicates the nucleus. L, M Quantitative assays for the number of MyHC + myotubes with 3–5 or more than 5 nuclei were performed six days after myoblast differentiation. Three independent experiments were performed, n = 3, *P < 0.05 vs. Ad-Null; #P < 0.05 vs. Ad-Ezrin; &P < 0.05 vs. Ad-Null; $P < 0.05 vs. Ad-shEzrin